Study of gut bacteria and TKIs in chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial looks at how gut bacteria affect the way chronic myeloid leukemia (CML) patients respond to tyrosine kinase inhibitor (TKI) medications. It may help doctors understand why some people have better outcomes than others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have chronic myeloid leukemia (CML)
- You are at any stage of CML, including newly diagnosed or later stages
- You are willing to have your gut bacteria tested
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
This study tracks the experiences and health outcomes of people with chronic myeloid leukemia (CML) who are taking approved first or second line tyrosine kinase inhibitor (TKI) medicines. It helps doctors learn how these treatments work in everyday care.
This study looks at how TKI medications, used to treat chronic myeloid leukemia (CML), may affect thyroid function. It will track patients starting TKI therapy to see if thyroid problems develop.
This trial is a real-life study that collects information from people living with chronic myeloid leukemia (CML). It may help doctors understand how CML treatments are used in practice and how well they work over time.
This study looks at the gut microbiome (tiny organisms in the gut) and metabolome (small chemicals in the body) in children and teens with newly diagnosed ALL. It may help researchers understand what is happening in the body early in treatment and could guide future, more personalized care.
This study uses a very sensitive blood test (digital PCR) to look for specific genetic mutations (changes) in the BCR::ABL1 gene in people with CML. The goal is to understand why some treatments stop working, which can help doctors choose the next best medication for you.
Hear when a new Leukemia,Myeloid, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.